Pharmaceutical companies have paid more than $127 billion in U.S. penalties since 2000, and big pharma lawsuits continue to reshape drug pricing, marketing, and safety practices today.1Violation Tracker. Pharmaceuticals The money has flowed through opioid settlements, fraud prosecutions, product liability verdicts, and, most recently, government price-negotiation fights. Some of the biggest cases are decades old and long resolved. Others are just heating up.
The Biggest Payouts on Record
A handful of companies account for a disproportionate share of the industry’s total penalties. Johnson & Johnson leads with more than $25 billion in cumulative penalties, followed by GSK, Pfizer, Merck, and Teva, each above $10 billion since 2000.1Violation Tracker. Pharmaceuticals
The single largest penalty on record is Johnson & Johnson’s $8.9 billion product safety payment in 2023 tied to its talcum powder litigation. Purdue Pharma’s $8.3 billion fraud penalty in 2020 for its role in the opioid crisis ranks second. Other top-tier cases include Merck’s $4.85 billion Vioxx settlement in 2007, Teva’s $4.25 billion opioid settlement in 2022, and Pfizer’s $3.75 billion drug safety penalty in 2002.1Violation Tracker. Pharmaceuticals
The Opioid Cases
The opioid epidemic produced the largest coordinated pharmaceutical litigation in American history. States, cities, counties, and tribal governments have collectively recovered more than $55 billion from manufacturers, distributors, pharmacies, and consulting firms.2Petrie-Flom Center at Harvard Law School. Opioid Settlement Funds: Are States Spending Them Wisely
Purdue Pharma and the Sacklers
The most prominent case involved Purdue Pharma, maker of OxyContin. Purdue filed for bankruptcy in September 2019 amid thousands of suits alleging that the company and its owners, the Sackler family, fueled the crisis through aggressive and deceptive marketing.3Office of the Attorney General of Pennsylvania. Purdue Sackler $7.4 Billion National Opioid Settlement Goes Into Effect The U.S. Supreme Court struck down a first settlement plan in June 2024, invalidating provisions that would have shielded the Sacklers from civil suits without all creditors’ consent.4NPR. Purdue Pharma Sacklers Reach New $7.4 Billion Opioid Settlement
A revised $7.4 billion plan was filed in March 2025 and received final court approval in November 2025, with more than 99 percent of voting creditors in favor.5Opioid Settlement Tracker. Global Settlement Tracker Unlike the earlier version, this plan lets creditors who decline the release provisions pursue independent claims against the Sacklers.4NPR. Purdue Pharma Sacklers Reach New $7.4 Billion Opioid Settlement
The settlement became effective May 1, 2026, signed by 55 attorneys general covering every eligible state and territory. The Sacklers paid $1.5 billion up front and Purdue contributed roughly $900 million, with further Sackler payments of about $500 million, $500 million, and $400 million scheduled through 2029.6Office of the Attorney General of Maryland. Attorney General Brown Announces Purdue Sackler $7.4 Billion Opioid Settlement to Go Into Effect7Commonwealth of Massachusetts. $7.4 Billion Settlement With Purdue Pharma and Sackler Family Goes Into Effect Purdue ceased operations that same day. Its manufacturing moved to Knoa Pharma LLC, a public benefit company owned by a nonprofit foundation, run by independent directors and barred from lobbying or advertising opioid products. Former Montana Attorney General and Governor Steve Bullock was appointed independent monitor, and the Sackler family is permanently banned from selling opioids in the United States.8New York Attorney General. Attorney General James Announces Shutdown of Opioid Manufacturer Purdue Pharma The deal also requires public release of more than 30 million internal Purdue documents.
Distributors, Retailers, and Advisors
A 2021 bipartisan deal brought $26 billion from the three largest drug distributors, McKesson, Cardinal Health, and AmerisourceBergen (now Cencora), plus Johnson & Johnson. The distributors agreed to pay up to $21 billion over 18 years and J&J up to $5 billion over nine.9National Association of Attorneys General. Opioids
A second wave of settlements resolved claims against CVS, Walmart, and Walgreens, along with manufacturers Allergan and Teva. Additional deals covered Kroger, a group of smaller generic opioid makers, and consulting firm McKinsey & Company, which paid $573 million across 47 states for its role advising Purdue on how to boost OxyContin sales.10North Carolina Opioid Settlement. National Settlements
Where the Money Goes
The settlements require that the substantial majority of funds go to opioid treatment, prevention, and recovery. Distribution formulas weigh overdose deaths, substance use disorder rates, prescription volume, and population.9National Association of Attorneys General. Opioids
In practice, oversight varies. As of early 2026, only ten states had published comprehensive spending reports. New Jersey’s legislature redirected $45 million to hospital systems without a specific addiction-services requirement, drawing public criticism from the state attorney general. In Ohio, a private nonprofit that received more than $440 million faced transparency complaints until the state Supreme Court ruled in 2023 that it was subject to public-records law. Even with those gaps, one study linked every additional dollar per capita of settlement spending in 2023 to a 2.46 percent decline in overdose deaths.2Petrie-Flom Center at Harvard Law School. Opioid Settlement Funds: Are States Spending Them Wisely
Fraud and Off-Label Marketing Cases
Before the opioid wave, the largest enforcement actions targeted fraud and illegal promotion of drugs for uses the FDA had not approved.
GlaxoSmithKline, $3 Billion in 2012
GSK’s 2012 settlement with the Department of Justice remains the largest healthcare fraud resolution in U.S. history. The company pleaded guilty to three criminal counts: two for introducing misbranded drugs into commerce and one for failing to report safety data to the FDA.11U.S. Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data
The criminal charges centered on three drugs. GSK promoted the antidepressant Paxil for unapproved pediatric use, including by misleadingly reporting a failed clinical trial as showing positive results. It marketed Wellbutrin for off-label uses such as weight loss and sexual dysfunction. And it withheld cardiovascular safety data from post-marketing studies on the diabetes drug Avandia. The $1 billion criminal portion covered fines and forfeiture. A $2 billion civil settlement resolved False Claims Act allegations involving off-label promotion and kickbacks to physicians for prescribing drugs including Advair, Lamictal, Zofran, Imitrex, Lotronex, Flovent, and Valtrex. GSK also paid $300 million for reporting false pricing data that caused the government to overpay on Medicaid rebates.11U.S. Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data No individual executives were charged.12The New York Times. GlaxoSmithKline Agrees to Pay $3 Billion in Fraud Settlement
Pfizer, $2.3 Billion in 2009
Pfizer subsidiary Pharmacia & Upjohn pleaded guilty in 2009 to a felony for marketing the anti-inflammatory drug Bextra for uses and dosages the FDA had specifically declined to approve, including post-operative pain in joint replacement patients. The criminal fine was $1.3 billion, at the time one of the largest ever imposed by the U.S. government.13Pfizer. Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department of Justice14FindLaw. Pfizer Hit With Largest Criminal Fine in US History The $1 billion civil component resolved False Claims Act allegations involving Bextra plus Geodon, Zyvox, and Lyrica. Whistleblower suits in Massachusetts, Pennsylvania, and Kentucky triggered the investigation. Pfizer also entered a five-year Corporate Integrity Agreement requiring compliance monitoring and independent review of its promotional practices.
Merck and Vioxx, $4.85 Billion in 2007
Merck pulled the painkiller Vioxx from the market in 2004 after a company-funded study found patients on the drug had twice the risk of heart attack and stroke compared with those on a placebo. The FDA had approved Vioxx in 1999 for osteoarthritis, acute pain, and menstrual pain.15PubMed Central. Merck and the Vioxx Settlement16BrownGreer. Vioxx
Active Cases to Watch
Johnson & Johnson Talcum Powder
Johnson & Johnson faces more than 67,000 pending lawsuits consolidated in a federal multidistrict litigation in New Jersey, alleging that its talc-based baby powder caused ovarian cancer and mesothelioma. Plaintiffs contend the company has known since the 1970s that its talc was contaminated with asbestos but did not warn consumers.17Drugwatch. Talcum Powder Lawsuits
J&J tried three times to use a bankruptcy maneuver known as the “Texas Two-Step,” creating a subsidiary, loading it with talc liabilities, and putting that subsidiary into bankruptcy, to resolve claims through a proposed $7 to $8 billion global settlement. A federal judge rejected the third attempt in early 2025, ruling J&J had not shown financial distress. The company chose not to appeal and withdrew the offer.17Drugwatch. Talcum Powder Lawsuits
With the bankruptcy stay lifted, verdicts have started coming in. J&J lost the first two ovarian cancer trials to reach a jury: $40 million in California in December 2025 and $250,000 in Philadelphia in February 2026. Mesothelioma verdicts have been far larger. A Baltimore jury awarded $1.5 billion to a single plaintiff in December 2025, believed to be the largest individual talc verdict to date. A California jury awarded $966 million, though a judge later vacated the $950 million punitive damages portion while leaving $16 million in compensatory damages intact. In January 2026, a special master recommended that plaintiffs be allowed to present expert testimony linking talc to ovarian cancer. In March 2026, The Lancet retracted a 1977 commentary on talc safety after discovering the author had been an undisclosed J&J consultant. J&J discontinued its talc-based baby powder globally in 2023.17Drugwatch. Talcum Powder Lawsuits
Ozempic and Other GLP-1 Drugs
Novo Nordisk and Eli Lilly face growing litigation over their GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound. As of April 2026, more than 3,546 cases alleging gastrointestinal injuries are consolidated in a federal MDL in the Eastern District of Pennsylvania. Plaintiffs allege the companies failed to adequately warn about risks including stomach paralysis, cyclic vomiting, intestinal obstruction, pancreatitis, and kidney injury.18Litpro. Ozempic Wegovy Litigation Updates Key Issues A second MDL addresses claims that the drugs cause nonarteritic anterior ischemic optic neuropathy, a form of permanent vision loss, citing a 2024 study in JAMA Ophthalmology.19Spencer-Law. Ozempic Lawsuit MDR Updates Eligibility Settlements
No settlements have been reached. Bellwether trials are not expected before late 2026 or early 2027. Some legal analysts have estimated Novo Nordisk’s potential liability at $2 billion or more.19Spencer-Law. Ozempic Lawsuit MDR Updates Eligibility Settlements
FTC Insulin Pricing Case
In September 2024, the Federal Trade Commission filed an administrative complaint against the three largest pharmacy benefit managers, Caremark Rx, Express Scripts, and OptumRx, alleging they engaged in anticompetitive rebating practices that inflated insulin prices. The FTC alleged the PBMs steered patients toward higher-cost insulin products so they could collect larger rebates from manufacturers.20BenefitsPro. Optum Rx Becomes Final PBM to Reach Settlement With FTC Over Insulin Pricing
All three moved toward settlement rather than trial. Express Scripts settled in February 2026 under terms projected to reduce patient out-of-pocket insulin costs by up to $7 billion over a decade. Caremark reached a proposed settlement in late March 2026, and OptumRx reached a tentative agreement by June 2026. All three denied the allegations.20BenefitsPro. Optum Rx Becomes Final PBM to Reach Settlement With FTC Over Insulin Pricing21Federal Trade Commission. In the Matter of Caremark Rx, Zinc Health Services, et al. (Insulin)
Pharma vs. Medicare Price Negotiation
The 2022 Inflation Reduction Act gave Medicare authority to negotiate prices for certain high-cost prescription drugs for the first time. The industry responded with at least 12 lawsuits arguing the program violated the Constitution and federal law.22Health Affairs. IRA Litigation: Pharma’s Failed Challenges to Medicare Drug Pricing
AstraZeneca, Bristol-Myers Squibb, Janssen, Novo Nordisk, Novartis, and Boehringer Ingelheim raised constitutional challenges under the Fifth Amendment’s Takings Clause, the First Amendment’s compelled speech doctrine, the Excessive Fines Clause, and due process. Courts rejected these arguments uniformly, with the Second and Third Circuits issuing six decisions against the industry. The courts consistently held that Medicare participation is voluntary and that drugmakers have no protected property interest in selling to Medicare at prices of their choosing.22Health Affairs. IRA Litigation: Pharma’s Failed Challenges to Medicare Drug Pricing
In May 2026, the U.S. Supreme Court declined to hear appeals from all six companies that had lost at the appellate level, leaving those rulings in place.23Medicare Rights Center. Supreme Court Declines to Hear Medicare Drug Price Negotiation Challenge A few cases remain pending. Teva is appealing a loss in the D.C. Circuit over the program’s second round, PhRMA’s challenge sits before the Fifth Circuit, and AbbVie filed a new suit in February 2026 arguing that Botox qualifies for a statutory exclusion for plasma-derived products.22Health Affairs. IRA Litigation: Pharma’s Failed Challenges to Medicare Drug Pricing
The first round of negotiated prices, covering ten drugs, took effect January 1, 2026. The program is projected to save the federal government $6 billion and reduce out-of-pocket costs for nine million Medicare beneficiaries by $1.5 billion in its first year.24Patients for Affordable Drugs. Patient Advocates, Legal Experts React to Supreme Court Denying Pharma Lawsuits
How These Cases Reach Court
Big pharma lawsuits generally split into two categories. Government enforcement actions target companies for fraud, safety violations, or regulatory misconduct. Product liability suits are brought by injured individuals or their families over harm caused by a drug.
Federal enforcement usually runs through the False Claims Act, which reaches companies that bill Medicare or Medicaid for drugs promoted through fraud, kickbacks, or off-label marketing. Many of the biggest cases were not started by government investigators but by company insiders filing under the FCA’s qui tam provisions, which let private citizens sue on the government’s behalf and collect between 15 and 30 percent of any recovery. In fiscal year 2018, qui tam suits produced 645 new filings and more than $2.1 billion recovered for the government. The GSK case yielded over $1 billion in whistleblower awards; a sales representative’s tip launched the Pfizer investigation; and a whistleblower in the 2013 Biogen Avonex kickback case received about $250 million from a $900 million settlement.
Individual product liability claims typically allege that a manufacturer failed to test a drug adequately, failed to warn about known risks, or sold a defective or contaminated product. Plaintiffs must generally show, through medical evidence and expert testimony, that the drug caused their specific injury. When thousands of similar claims arise against the same manufacturer, federal courts consolidate them into multidistrict litigation for pretrial proceedings. Each plaintiff’s injuries are evaluated individually, unlike in a class action where a single outcome binds the whole group. Early “bellwether” trials test representative claims and often drive settlement talks by showing both sides the likely range of outcomes. Statutes of limitations vary by state, generally running one to six years from when an injury is discovered.